 |
submitted by /u/Philip19967 [link] [comments] |
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
https://ift.tt/70JXyws January 07, 2023 at 01:47AM https://ift.tt/wNyozf9
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment